Rituximab biosimilars for lymphoma in Europe-Reference-Cited by-同舟云学术

Rituximab biosimilars for lymphoma in Europe

Published:2019-09-30 Issue:10 Volume:19 Page:1045-1056
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Jurczak Wojciech¹^ORCID,Długosz Danecka Monika¹,Buske Christian²

Affiliation:

1. Oncology Centre, Maria Skłodowska-Curie Institute, Kraków, Poland

2. Comprehensive Cancer Center Ulm, Institute for Experimental Tumor Research, University Hospital Ulm, Ulm, Baden-Württemberg, Germany

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2019.1665017

Reference118 articles.

1. European Medicines Agency. MabThera summary of product characteristics (SmPC) 2016. Available from: https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf

2. Rituximab The First Monoclonal Antibody Approved for the Treatment of Lymphoma

3. A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas

4. Past, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody Therapy

5. Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-Term Safety and Effectiveness of Rituximab Biosimilar RTXM83: A Retrospective Extension Study in Brazilian Patients with Diffuse Large B-Cell Lymphoma;Oncology and Therapy;2024-06-03

2. The efficacy and safety of rituximab with or without glucocorticoid in inducing remission of MCD with different clinical presentations in adults: a retrospective study;Clinical Kidney Journal;2024-05-03

3. Fusion of dual-targeting peptides with MAP30 promotes the apoptosis of MDA-MB-231 breast cancer cells;2024-03-25

4. Incidence, clinical features, and survival outcomes of primary malignant lacrimal gland tumors: A population‐based analysis;Cancer Medicine;2024-01-17

5. Biosimilar in Cervical Cancer;Biosimilars for Cancer Treatment;2024